Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px
Organisation › Details

GenSight Biologics S.A. (Euronext: SIGHT)

GenSight Biologics S.A. (GenSight) is a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye, and in the future, of the central nervous system. GenSight’s integrated development includes two core technology platforms, mitochondrial targeting sequence (MTS) and optogenetics, to help preserve or restore vision in patients with severe retinal diseases. GenSight’s lead product, GS010, is poised to enter a pivotal Phase III trial for vision loss in Leber’s Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible sight loss in teens and young adults. Using its gene therapy-based approach, GenSight’s product candidates are designed to be administered in a single treatment to each eye by intravitreal or subretinal injection in order to provide patients with a long-lasting functional cure, potentially for the rest of their lives. *

 

Period Start 2013-04-08 existent
Products Industry ophthalmic
  Industry 2 gene therapy
Persons Person Gilly, Bernard (GenSight Biologics 201304 CEO + Co-founder before Fovea + Sofinnova Partners + Transgene)
  Person 2 Gidoin, Thomas (GenSight Biologics 201507 CFO)
     
Region Region Paris
  Country France
  Street 74 rue du Faubourg Saint-Antoine
  City 75012 Paris
  Tel +33-1-7621-7220
    Address record changed: 2018-07-24
     
Basic data Employees n. a.
  Currency EUR
  Annual sales 3,000,665 (income, operation (2016) 2016-12-31)
  Profit -22,018,686 (2016-12-31)
  Cash 63,600,000 (2017-06-30)
     
    * Document for �About Section�: GenSight Biologics S.A.. (7/23/15). "Press Release: GenSight Biologics Closes $36 Million Series B Preferred Stock Financing". Paris.
     
   
Record changed: 2018-10-31

Advertisement

Picture [iito] – Putting Information into Context 600x60px

More documents for GenSight Biologics S.A. (Euronext: SIGHT)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Partnering 600x60px




» top